Is the price fair?
What PEN's price assumes
Penumbra, Inc. trades at 74.5× earnings against 33.4× for the median Medical Devices name, more expensive than its own group.
74.5
Trailing P/E · Medical Devices median 33.4 · 2.23× the median: the market pays up for this one
- Price / sales
- 8.93
Price / sales · as of 2026-Q1
- Free cash flow yield
- 1.7%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +20%
Growth the price implies · The price pays for +20% free cash flow growth a year for a decade; revenue has grown +18% a year over the last three.
Details›
- Price / book2026-Q1
- 8.81
- Healthcare median P/E362 names
- 31.5
- Medical Devices median P/E39 names
- 33.4
- Free cash flow, trailing twelve months
- $213M
- Market capitalisation
- $12.5B
- 3-year revenue growth
- +18%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Devices
Ranks #19 of 35 by Smart Score